MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

About this update from Maxcyte, Inc.

[{"type":"image","alt":"MaxCyte, Inc","displaySize":"","headline":null,"caption":"MaxCyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WYwJtM4XDMnm8G2fGhEvjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a","width":300,"height":45}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance.","length":380,"tagName":"p"},{"type":"text","content":"First Quarter and Recent Highlights","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Core business revenue of $8.2 million in the first quarter of 2025, an increase of 1% over the first quarter of 2024.","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Platform License (SPL) Program-related revenue was $2.1 million for the first quarter of 2025, compared to $3.2 million in the first quarter of 2024.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue of $10.4 million in the first quarter of 2025, a decrease of 8% over the first quarter of 2024.","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"MaxCyte added one new SPL client, TG Therapeutics, in February. The total number of active SPLs stands at 29.","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Total cash, cash equivalents and investments were $174.7 million as of March 31, 2025.","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":580,"olType":false},{"type":"text","content":"“MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength in PAs,” said Maher Masoud, President and CEO of MaxCyte. “We’ve added one new SPL thus far in 2025, TG Therapeutics in February, and continue to see a robust pipeline of SPL opportunities ahead of us. As we progress t...

More updates from Maxcyte, Inc.